Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Salesforce

NEXTracker Inc

Palo Alto Networks

UiPath

SoFi Technologies

Block

In the vast equities landscape, hidden gems are waiting to be unearthed. Like diamonds in the rough, these undervalued stocks possess the potential to shine brightly in an investment portfolio.

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Wisdomtree BioRevolution Fund

Intellia Therapeutics

The healthcare sector is disappointing this year. And the ICE Biotechnology Index is even more of a dud on a year-to-date basis.

Multiple Reasons to Bet on Biotech ETF WDNA

Biogen

bluebird bio

BioMarin Pharmaceutical

Editas Medicine

Novartis

Regeneron Pharmaceuticals

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Tesla

Cathie Wood is a visionary investor with an eye toward disruptive new technology. Tesla and Crispr Therapeutics are two of her top holdings that screen as stellar buys right now.

2 Cathie Wood Stocks to Buy Hand Over Fist Right Now

CRISPR Therapeutics has a partnership with Vertex over Exa-Cel, a potentially curative therapy for Sickle Cell Disease and beta thalassemia. The FDA will hold an Advisory Committee meeting before the December 8 decision on Exa-Cel's approval. CEO Sam Kulkarni aims to grow CRISPR Therapeutics into a $25 billion company, comparing it to the rise of RNA therapeutics giants like Alnylam Therapeutics.

CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Step

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

AbbVie

Amgen

Johnson & Johnson

Eli Lilly

Molina Healthcare

Merck

Novo Nordisk

Pfizer

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

Gilead Sciences

Many gene-editing biotechs are developing cures. Curing patients is good.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

Advanced Micro Devices

Medtronic

Moderna

NVIDIA

Vertex Pharmaceuticals

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

Recursion Pharmaceuticals

The timing of upcoming catalysts is a key consideration when comparing biotechs. Recursion Pharmaceuticals may make more revenue soon, but not from its pipeline.

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics

Medtronic delivers a solid dividend as well as strong returns. CRISPR Therapeutics could soon have its first approved therapy on the market.

3 Top Healthcare Stocks Defying the Bear Market

Medical device giant Medtronic recently lifted its annual earnings guidance. CRISPR Therapeutics is heading for a major milestone: a regulatory decision on what may become its first product.

Better Bull Market Buy: CRISPR vs. Medtronic Stock

Abeona Therapeutics

Vaxart

Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.

3 Biotech Blockbusters to Turn $5,000 Into $50,000

Bluebird Bio and CRISPR Therapeutics are unprofitable companies focused on gene editing. However, both biotechs are on the verge of winning important regulatory approvals.

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

I warned investors in June 2022 to be wary about adding Crispr Therapeutics stock. My Sell rating has panned out accordingly as CRSP significantly underperformed the S&P 500. Despite that, CRSP bottomed out in December 2022, in the first sign of a capitulation buy that investors loaded up with conviction. The company is on track for its first approval, which could pave the way toward its commercial entry, bolstering buying sentiments further.

Crispr Therapeutics: The Chance To Load Up Is Finally Here (Technical Analysis)

Shares of CRISPR Therapeutics (NASDAQ: CRSP ) — which specializes in gene-editing innovations — are tumbling on Thursday. The red ink follows an announcement that co-founder, President and Chairman Rodger Novak will step down from the company effective Sept.

CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down

-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company-

CRISPR Therapeutics Announces Leadership Transition

CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citigroup Yigal Nochomovitz We can get started. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi.

CRISPR Therapeutics AG (CRSP) Presents at Citi's 18th Annual BioPharma Conference Transcript

CRISPR Therapeutics is awaiting the FDA's approval decision on its most advanced treatment candidate. Recursion Pharmaceuticals is a clinical-stage drugmaker applying artificial intelligence to the drug-discovery process.

2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street

CRISPR Therapeutics already has increased more than 20% this year. Significant catalysts lie ahead for the biotech, including the potential approval of its first product.

With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?

Bio-Rad Laboratories

Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over.

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

Accolade

Invitae

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi's 18th Annual Biopharma Conference being held from September 6-7, 2023.

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

Caribou Biosciences

Biotechs tend to be very risky investments. Picking businesses with good management and plenty of cash can reduce risk.

3 Clever Tricks to Find Winning Biotech Stocks

News for CRISPR Therapeutics Stock (CRSP)